Welireg® (belzutifan)
for Renal Cell Carcinoma
Welireg (belzutifan) is used to treat von Hippel-Lindau (VHL) disease by reducing tumor size, including central nervous system hemangioblastomas, pancreatic neuroendocrine tumors, and renal cell carcinomas. It is also used to treat advanced renal cell carcinoma (RCC) in certain adults. Welireg works as a hypoxia-inducible factor (HIF) inhibitor, blocking HIF-2a, a protein that contributes to tumor growth due to a mutation in the VHL tumor suppressor gene.
